Related Experiment Video
Updated: Nov 23, 2025
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
14.3K
Viral Vector Vaccines against Bluetongue Virus
Luis Jiménez-Cabello1, Sergio Utrilla-Trigo1, Eva Calvo-Pinilla1
1Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, 28130 Madrid, Spain.
Microorganisms
|December 30, 2020
Summary
Bluetongue virus (BTV) causes a livestock disease transmitted by midges. This review outlines live viral vector vaccines against BTV, addressing limitations of traditional vaccines for bluetongue (BT) control.
Area of Science:
- Veterinary Virology
- Immunology
- Infectious Diseases
Background:
- Bluetongue virus (BTV), an orbivirus, causes bluetongue (BT) in livestock, transmitted by Culicoides midges.
- BTV distribution is expanding, with outbreaks in Europe, necessitating improved control strategies.
- Traditional vaccines (live-attenuated, inactivated) have limitations in safety, efficacy, cross-protection, and DIVA strategy implementation.
Purpose of the Study:
- To provide a comprehensive overview of live viral vector vaccines developed against Bluetongue virus.
- To highlight the potential of recombinant vaccine technologies for BTV control.
- To discuss how novel vaccine approaches can overcome challenges posed by classical BTV vaccines.
Main Methods:
- Review of scientific literature on BTV vaccine development.
- Focus on recombinant viral vector vaccine prototypes against BTV.
- Analysis of vaccine safety, efficacy, cross-protection, and DIVA compatibility.
Main Results:
- Various recombinant viral vector vaccine prototypes against BTV have been investigated.
- Live viral vectors offer potential advantages over classical vaccine approaches.
- Research is ongoing to develop effective and safe BTV vaccines.
Conclusions:
- Live viral vectors represent a promising alternative for developing next-generation bluetongue vaccines.
- These novel approaches aim to improve vaccine safety, broaden protective responses, and facilitate disease surveillance.
- Further research and development are crucial for the successful implementation of viral vector vaccines against BTV.
